GSC000190 / GeneScience - LARVOL DELTA

GSC000190, a highly potent inhibitor of KIF18A, for tumors with chromosome instability (AACR 2024) - "In vivo, GSC000190, at approximately one tenth of systematic exposure comparing to that of AMG650, the leading clinical KIF18A inhibitor, causes tumor shrinkage in multiple CDX models including ovarian, colon and lung cancers. In an HGSOC PDX model which is resistant to platinum and olaparib, GSC000190 induced strong tumor regression both as single agent and through combination without significant body weight reduction...GSC000190 has a favorable ADME profile in rodents, dogs and NHPs, as well as a much better safety profile. GSC000190 is now under IND-enabling study and P1 study is planned in the second quarter of 2024.Legal entity responsible for the study: The authors.Disclosure: All authors have declared no conflicts of interest."

Colon Cancer • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • KIF18A